Where next for QOF?

Killing the Quality and Outcomes Framework won’t decrease prescribing for depression

BMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f2742 (Published 3 May 2013)
Cite this as: BMJ 2013;346:f2742

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Tony Kendrick, professor of primary care1
  1. 1Hull York Medical School, University of York, York YO10 5DD, UK
  1. tony.kendrick{at}hyms.ac.uk

Gillam and Steel imply that the Quality and Outcomes Framework (QOF) has contributed to increased prescribing of antidepressants.1 Where is the evidence? Prescriptions of selective serotonin reuptake inhibitors have risen steadily since their introduction in several countries,2 only one of which has a QOF.

We found that prescription increased due to small increments in the proportion of patients put on long term treatment over …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL